Breaking News, Collaborations & Alliances

Novo Nordisk Enters Exclusive License Agreement with Lexicon for LX9851

Obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications.

Author Image

By: Charlie Sternberg

Associate Editor

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for completing agreed upon Investigational New Drug (IND) application-enabling activities for LX9851....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters